---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（201941619155022.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文欧乃派克处方资料（仅供参考）

【英文名称】Omnipaque

【适应症】

OMNIPAQUE 180，OMNIPAQUE 240和OMNIPAQUE 300适用于成人鞘内注射，包括脊髓造影（腰椎，胸椎，颈椎，全柱状）和对比增强计算机断层扫描（脊髓造影，脑池造影，脑室造影）。

OMNIPAQUE 180适用于儿童鞘内给药，包括脊髓造影（腰椎，胸椎，颈椎，全柱状），以及计算机断层扫描（脊髓造影，脑池造影）的对比增强。

【禁忌】

OMNIPAQUE不应给予已知对碘海醇超敏反应的患者。

在可能出现菌血症的明显局部或全身感染的情况下，不应进行脊髓造影。

禁止用OMNIPAQUE鞘内注射皮质类固醇。

由于过量使用的可能性，在技术失败的情况下立即重复脊髓造影是禁忌的（参见剂量和用法）。

【用法和用量】

OMNIPAQUE 180，OMNIPAQUE 240或OMNIPAQUE 300的体积和浓度将取决于所检查区域和所用设备和技术所需的对比度和程度。 建议将浓度为180 mgI / mL的OMNIPAQUE 180，浓度为240 mgI / mL的OMNIPAQUE 240或浓度为300 mgI / mL的OMNIPAQUE 300用于腰椎，胸部和颈部区域的检查在成人中通过腰椎或直接颈椎注射并且对CSF有轻度高渗。 推荐使用浓度为180 mgI / mL的OMNIPAQUE 180进行腰椎注射检查儿童的腰椎，胸椎和颈椎部位，并且对脑脊液轻度高渗。

成人不应超过3060 mg碘或300 mgI / mL的总剂量，单个脊髓造影患儿的总剂量不得超过2700 mg碘或180 mgI / mL检查。这是基于迄今为止的临床试验评估。与所有诊断程序一样，产生的最小体积和剂量 应该使用足够的可视化。大多数程序不需要最大剂量或浓度。

麻醉不是必需的。通常不需要术前镇静剂或镇静剂（参见注意事项）。在造影剂施用之前和之后，患者应该充分水合。易患癫痫的患者应坚持服用抗惊厥药物。许多不透射线造影剂在体外与一些抗组胺药和许多其他药物不相容;因此，并发药物不应与造影剂物理混合。

注射速度：为避免与CSF过度混合并随后稀释造影剂，应在1至2分钟内缓慢注射。

取决于手术可能需要的造影剂的估计体积，可以去除少量CSF以最小化蛛网膜下腔的扩张。

腰椎或宫颈穿刺针可在注射后立即取出，因为在注射到蛛网膜下腔后不必除去OMNIPAQUE。

【INDICATIONS AND USAGE】

OMNIPAQUE 180, OMNIPAQUE 240, and OMNIPAQUE 300 are indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography).

OMNIPAQUE 180 is indicated for intrathecal administration in children including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography).

【CONTRAINDICATIONS】

OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.

Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely.

Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated.

Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see DOSAGE AND ADMINISTRATION).

【DOSAGE AND ADMINISTRATION 】

The volume and concentration of OMNIPAQUE 180, OMNIPAQUE 240, or OMNIPAQUE 300 to be administered will depend on the degree and extent of contrast required in the area(s) under examination and on the equipment and technique employed.

OMNIPAQUE 180 at a concentration of 180 mgI/mL, OMNIPAQUE 240 at a concentration of 240 mgI/mL, or OMNIPAQUE 300 at a concentration of 300 mgI/mL is recommended for the examination of the lumbar, thoracic, and cervical regions in adults by lumbar or direct cervical injection and is slightly hypertonic to CSF.

OMNIPAQUE 180 at a concentration of 180 mgI/mL is recommended for the examination of the lumbar, thoracic, and cervical regions in children by lumbar injection and is slightly hypertonic to CSF.

A total dose of 3060 mg iodine or a concentration of 300 mgI/mL should not be exceeded in adults and a total dose of 2700 mg iodine or a concentration of 180 mgI/mL should not be exceeded in children in a single myelographic examination. This is based on clinical trial evaluation to date. As in all diagnostic procedures, the minimum volume and dose to produce adequate visualization should be used. Most procedures do not require either maximum dose or concentration.

Anesthesia is not necessary. Premedication sedatives or tranquilizers are usually not needed (see PRECAUTIONS). Patients should be well hydrated prior to and following contrast administration. Seizure-prone patients should be maintained on anticonvulsant medication. Many radiopaque contrast agents are incompatible in vitro with some antihistamines and many other drugs; therefore, concurrent drugs should not be physically admixed with contrast agents.

Rate of Injection: To avoid excessive mixing with CSF and consequent dilution of contrast, injection should be made slowly over 1 to 2 minutes.

Depending on the estimated volume of contrast medium which may be required for the procedure a small amount of CSF may be removed to minimize distention of the subarachnoid spaces.

The lumbar or cervical puncture needle may be removed immediately following injection since it is not necessary to remove OMNIPAQUE after injection into the subarachnoid space.

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（201941619155022.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------